Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fumoleau

Showing results (71-80 of 152) with videos related to

Pageof 16
Sort By:
Breast Cancer Research and Treatment|January 1, 1993
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifenE Garcia-Giralt, Y Ayme, M Carton, et al.
La Clinica Terapeutica|August 1, 1994
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]E Garcia-Giralt, C Omodei Zorini, L Ferri, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2007
Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumoursH Bourgeois, J Vermorken, G Dark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancerB Chevallier, P Chollet, Y Merrouche, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC)J Chauvergne, P Fumoleau, P Cappelaere, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2009
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic studyP Marino, C Siani, H Roché, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Fotemustine plus dacarbazine for malignant melanomaM F Avril, J Bonneterre, D Cupissol, et al.
Journal of Neuro-Oncology|February 24, 2001
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adultsH Roche, H Cure, A Adenis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of CancerB Chevallier, P Fumoleau, P Kerbrat, et al.
Drugs Under Experimental and Clinical Research|January 1, 1986
Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal resultsG Mathé, J L Misset, R Plagne, et al.
Pageof 16

Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|January 1, 1993
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifenE Garcia-Giralt, Y Ayme, M Carton, et al.
La Clinica Terapeutica|August 1, 1994
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]E Garcia-Giralt, C Omodei Zorini, L Ferri, et al.
Cancer Chemotherapy and Pharmacology|June 2, 2007
Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumoursH Bourgeois, J Vermorken, G Dark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancerB Chevallier, P Chollet, Y Merrouche, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC)J Chauvergne, P Fumoleau, P Cappelaere, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2009
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic studyP Marino, C Siani, H Roché, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Fotemustine plus dacarbazine for malignant melanomaM F Avril, J Bonneterre, D Cupissol, et al.
Journal of Neuro-Oncology|February 24, 2001
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adultsH Roche, H Cure, A Adenis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of CancerB Chevallier, P Fumoleau, P Kerbrat, et al.
Drugs Under Experimental and Clinical Research|January 1, 1986
Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal resultsG Mathé, J L Misset, R Plagne, et al.
Pageof 16